Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Pityriasis rubra pilaris awareness

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Erythrodermic PRP

Pityriasis rubra pilaris can generalise into erythroderma with shivering, temperature dysregulation, fluid loss, oedema, infection and cardiorenal strain.

Action: Arrange immediate same-day dermatology and acute medical assessment, check ABCDE and fluid balance, and begin gentle barrier support while excluding infection, drug reaction and other erythrodermas.

Synopsis

Recognise the distinctive follicular, palmoplantar and island-sparing pattern of pityriasis rubra pilaris, confirm rare disease thoughtfully, protect erythrodermic physiology, and refer for specialist treatment.

  • PRP is a rare inflammatory keratinisation disorder characterised by rough follicular papules, coalescing orange-red or brown-red scaly plaques, islands of sparing and waxy palmoplantar keratoderma.
  • Classic adult PRP often starts on scalp or face and spreads downwards; orange colour may be subtle in deeply pigmented skin, so texture, follicular plugging and spared islands are more reliable.
  • Palms and soles become thick, orange or waxy and fissured; pain, walking and hand function are essential severity outcomes.
  • Diagnosis is clinical with dermatology confirmation; biopsy can support the pattern and exclude psoriasis, drug eruption or lymphoma, but no blood test confirms PRP.
  • Classic adult type has the most favourable natural history, with BAD reporting spontaneous clearance in up to 80% within three years, while atypical and familial forms may persist.
  • Limited disease uses regular emollient, keratolytic and site-appropriate topical corticosteroid for symptoms; these may reduce inflammation without shortening the whole disease course.
  • Extensive disease requires specialist treatment, commonly off-label acitretin or methotrexate and sometimes phototherapy or biologic therapy after careful diagnosis and monitoring.
  • Erythroderma with shivering, fluid loss or systemic instability requires immediate same-day specialist assessment and acute barrier-failure care.

Key red flags

Near-total skin inflammation with shivering, fever or hypothermia, tachycardia, oedema, reduced urine output or breathlessness requires emergency assessment.

Skin pain, mucosal erosions, dusky targets, blistering or a recent high-risk medicine suggests severe drug reaction rather than uncomplicated PRP.

Rapidly spreading warmth, purpura, focal disproportionate pain or haemodynamic compromise raises concern for invasive infection and needs immediate sepsis and surgical assessment.

Marked palmoplantar fissuring that prevents walking or hand use, nutritional compromise or severe distress warrants expedited specialist support even without erythroderma.

Erythrodermic deterioration

Near-total involvement with shivering, temperature change, oedema, tachycardia, oliguria or breathlessness indicates barrier failure and needs immediate acute care.

Investigation priorities

01
First-line full skin, scalp, nail and mucosal examinationFirst stepFirst line

Identify follicular papules, direction of spread, islands of sparing, palmoplantar keratoderma and features of competing erythrodermas.

Management branches

First-lineConfirm the rare diagnosis

Follicular papules, spared islands and palmoplantar keratoderma suggest PRP without physiological instability.

  1. Document onset, direction of spread, family and medicine history, HIV risk, full morphology and functional impact across skin tones.
  2. Refer to dermatology for confirmation and select a representative biopsy when psoriasis, drug eruption, lymphoma or inherited keratinisation disease remains plausible.
  3. Explain uncertainty and natural history honestly: classic adult disease often clears spontaneously, but subtype and treatment response vary and review may refine the label.

Key medicines

Emollient or soap substituteApply generously and frequently to dry or fissured skin and use as a wash substitute, coordinating applications with active treatment and non-adhesive dressings.Fabric and hair contamination increases fire severity even after drying; avoid flames and smoking, wash fabrics frequently, prevent slips and stop additives that sting erythrodermic skin.
Betamethasone valerate 0.1% cream or ointmentApply thinly to appropriate active plaques once or twice daily for up to 4 weeks, then reduce frequency or step down after improvement.Avoid face, flexures, widespread erythroderma, untreated infection and unplanned occlusion; reassess diagnosis if worse or unimproved within 2 to 4 weeks.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists: pityriasis rubra pilaris
  • Primary Care Dermatology Society: pityriasis rubra pilaris
  • Acitretin capsules Summary of Product Characteristics
  • Betamethasone valerate cream Summary of Product Characteristics
  • MHRA: safe use of emollient skin creams

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom